Moderna, Inc. vs Incyte Corporation
A head-to-head of Moderna, Inc. (MRNA) and Incyte Corporation (INCY) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | MRNA | INCY |
|---|---|---|
| Market Cap | $19.47B | $19.57B |
| P/E (TTM) | — | 13.84 |
| Forward P/E | -10.81 | 10.52 |
| P/S | 8.44 | 3.55 |
| P/B | 2.61 | 3.48 |
| EV/EBITDA | -6.46 | 9.71 |
| Dividend Yield | — | — |
| Profit Margin | -144.92% | 26.71% |
| Gross Margin | 54.84% | 92.76% |
| Operating Margin | -159.94% | 26.12% |
| Revenue Growth (YoY) | +263.55% | +20.87% |
| FCF Yield | -8.54% | 7.47% |
| Debt / Equity | 7.96 | 0.70 |
| Current Ratio | 2.41 | 3.68 |
Share:
Compare Moderna, Inc. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.